Seminars in Oncology
Volume 36, Issue 3 , Pages 237-249, June 2009

Breast Cancer Before Age 40 Years

  • Carey K. Anders

      Affiliations

    • University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
    • Corresponding Author InformationAddress correspondence to Carey K. Anders, MD, Assistant Professor, Hematology-Oncology, University of North Carolina at Chapel Hill, 170 Manning Dr, POB 3119, Campus Box 7305, Chapel Hill, NC 27599-7305
  • ,
  • Rebecca Johnson

      Affiliations

    • Seattle Children's Hospital, Seattle, WA
  • ,
  • Jennifer Litton

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, TX
  • ,
  • Marianne Phillips

      Affiliations

    • Princess Margaret Hospital for Children, Perth, Australia
  • ,
  • Archie Bleyer

      Affiliations

    • St. Charles Medical Center, Bend, OR

Approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this disease accounts for more than 40% of all cancer in women in this age group. Survival rates are worse when compared to those in older women, and multivariate analysis has shown younger age to be an independent predictor of adverse outcome. Inherited syndromes, specifically BRCA1 and BRCA2, must be considered when developing treatment algorithms for younger women. Chemotherapy, endocrine, and local therapies have the potential to significantly impact both the physiologic health—including future fertility, premature menopause, and bone health—and the psychological health of young women as they face a diagnosis of breast cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(09)00037-2

doi:10.1053/j.seminoncol.2009.03.001

Seminars in Oncology
Volume 36, Issue 3 , Pages 237-249, June 2009